Search PubMed⌕ Search

Biomedical subjects

M Tremoulet

Publications and source records attributed to M Tremoulet.

51 records · Page 3Linked to original sources
PubMedDate not supplied

Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.

The aim of the study was to evaluate the short term and long-term effects of long acting repeatable bromocriptine (= Parlodel-LAR*) in patients with macroprolactinomas. Twenty-nine patients (15 men and 14 women) aged 42 +/- 2.7 (M +/- SEM) years were injected with Parlodel-LAR* every 4 weeks during 3.3 +/- 0.3 years. The starting dose was 50 mg/injection, then it was increased to 100 mg in 11 patients and 150 mg in 9 patients. PRL levels decreased in all but one patient 4 weeks after the first injection (270 +/- 59 vs 934 +/- 210 ng/ml, p < 0.001), then became less than 20 ng/ml in 20/29 (69%) patients and finally became undetectable or low in 13/29 (45%) patients. Visual field defects were present in 12/29 patients before treatment. In 11/12 patients, treatment with Parlodel-LAR* resulted in an improvement and complete correction of visual field defects was observed in 8/12 patients. Adenoma size (2.5 +/- 0.2 cm before treatment) was reduced by at least 20% in 24/29 (83%) patients. Disappearance of adenoma was observed on CT scan in 8/29 (28%) patients after 28.7 +/- 5.3 months of treatment. Minor side effects occurred in 20 patients after the first injection then disappeared in 18 patients within the following 6 months of treatment. One patient had rhinorrhea after 3 months of treatment. Treatment with Parlodel-LAR* results in beneficial short-term effects (with rapid correction of recent onset visual field defects) and long-term effects (which can include complete disappearance of adenoma on CT scan evaluation) in patients with macroprolactinomas.

Adult↗
PubMedDate not supplied

The prognostic value of noninvasive CBF measurement in subarachnoid hemorrhage.

Seventy-four measurements of cerebral blood flow (CBF) were performed using the Xenon 133 inhalation method in 50 cases of spontaneous subarachnoid hemorrhage. This method is non-traumatic, reproducible and dependable. A correlation was found between clinical condition and CBF values, but in a number of cases which cannot be dismissed, very low mean CBF values or ischemic foci were revealed where clinical state gave no indication of same. A poor correlation appeared between vasospasm seen by angiography and ischemic foci detected by isotopic technique. Patients' age influenced CBF values but not clinical evolution. CBF values, measured in the first two weeks of illness, were significantly higher in those patients having favorable outcome, whatever their clinical state at the time of CBF measurement (comas excluded). The figure of 60 ml/100g/min. for mean cortical flow seemed to be a critical level below which risk of complications was greater. Conversely, in every case where mean cortical flow measured above 70 ml, outcome was favorable. Thus, CBF measurement promises to be a valuable prognostic tool, playing an important role in the therapeutic strategy for this type of patient.

Adult↗
PubMedDate not supplied

Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.

A non randomized pilot study has been undertaken to evaluate the feasibility of local immunotherapy (IT) of recurrent glioblastoma multiforme (GM) by continuous intracerebral perfusion of recombinant interleukin-2 (rIL-2, Eurocetus) with and without lymphokine activated killer (LAK) cells. At time of surgical removal of the tumor, a catheter was implanted in the cavity left by tumor debulking allowing continuous perfusion of rIL-2. Five patients received 18 x 10(6) IU/day or rIL-2 for five days. At days 1, 3, and 5 after surgery, rIL-2 perfusion was briefly interrupted for the injection of LAK cells. Eight other patients received rIL-2 alone, either 24 x 10(6) IU/day (five patients) or 54 x 10(6) IU/day (three patients). Capillary leak syndrome, which is the main side effect of systemic infusion of rIL-2, was never observed, but local immunotherapy induced fever, confusion, and cerebral edema in all patients. Despite local IT, tumor progression was diagnosed by CT scan 4 to 12 weeks after the treatment.

Adult↗